Cancer, Somatic Mutation
Conditions
Brief summary
Recently technology has been developed at the Wellcome Sanger Institute to allow clusters of cells with mutations to be detected in normal and diseased tissues. The researchers wish to determine how the number and nature of these mutant cell clusters change in response to treatments given to cancer patients (such as chemotherapy, radiotherapy, immunotherapy, and drugs targeted at specific mutations in tumours). As such the researchers wish to collect research samples of blood, cheek cells (via swabs) and urine from adult cancer patients receiving the above-mentioned treatments as part of their standard care. The researchers also wish to access any leftover tissue following surgery that is undertaken as part of these patient's treatment.
Detailed description
Disease and tissue aging are thought to be influenced by genetic changes, or mutations, acquired throughout life. These mutations provide clues regarding the genetic damage that occurred through the lifetime of the patient, and include mutations caused by environmental factors such as ultraviolet light from sunlight or tobacco smoke affecting the skin or internal tissues, respectively. Other mutations may occur due to errors in copying the genome as cells divide. Once a cell has acquired a mutation, the cell's daughters may inherit it. Eventually clusters of cells carrying the same mutation may form within tissues. If the mutations alter cell behaviour this may impact how cells behave and influence how a whole tissue functions.
Interventions
OTHERsample collection
Participants may collected their own cheek swabs and will collect their own urine samples. Clinical professionals at participating sites will collect blood samples.
OTHERDiscussing study
Research Nurse/ Suitably qualified Research Site Staff will discuss the study with potential participants
OTHERSeeking consent
Potential participants who wish to give consent will do with a Research Nurse/ Suitably qualified Research Site Staff.
Sponsors
The Wellcome Sanger Institute
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Male or Female * Due to commence systemic treatment for histologically confirmed cancer at a - participating site * Age over 18 years * Able to give informed consent. * Able to give urine, blood and cheek swab samples on two occasions. * Likely to complete 3 months of treatment
Exclusion criteria
* Anyone outside of the inclusion criteria plus individuals who Lack the capacity to provide informed consent and those who do not have a good command of the English language. * Any participant who is known to have Hep B, Hep C or HIV
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To measure the size of acquired (somatic) mutations | 5 years | The study will measure the size of acquired (somatic) mutations in clusters of cells in normal blood, urinary tract and oral cells changes after cancer treatment. |
| To measure the frequency of acquired (somatic) mutations | 5 years | The study will measure the frequency, size and nature of acquired (somatic) mutations in clusters of cells in normal blood, urinary tract and oral cells changes after cancer treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To understand the nature of acquired (somatic) mutations | 5 years | The study will attempt to define and/or understand the behaviour/ nature of acquired (somatic) mutations in clusters of cells in normal blood, urinary tract and oral cells changes after cancer treatment. |
Countries
United Kingdom
Outcome results
None listed